Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MYGN
MYRIAD GENETICS, INC.
NASDAQ
$3.16
▼ DOWN 0.63% (-0.02)

KEY STATISTICS

Market Cap$298.46 M
52w High$8.59
52w Low$2.74
Dividend Yield13.45%
FrequencyMonthly
P/E-24.31
Volume1.43M
Shares Out.94.45M

COMPANY

LEADERSHIP

Samraat S. Raha
CHIEF EXECUTIVE
Samraat S. Raha

COMPENSATION 2026

Salary$856,901
Stock Awards$3,989,729
Incentive Plan Pay$814,660
All Other Comp.$25,450
Total$5,686,740

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 6, 1995
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
2,700

PRICE TARGET

Target High$3.00
Target Low$3.00
Target Median$3.00
Target Consensus$3.00

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.$191.32M
NOV
2
MON

SPLIT RECORD

DATETYPERATIO
2009-03-26Forward2:1
2000-09-12Forward2:1

PRICE

$3.16 ▼ DOWN 0.63% (−$0.02)
OVERLAYS
$3.08$3.12$3.16$3.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.16

About Myriad Genetics, Inc.

https://www.myriad.com ↗

Myriad Genetics develops and commercializes genetic tests for oncology, women's, and mental health applications, including hereditary cancer, tumor, prenatal, and mental health diagnostics globally.

INDUSTRY

Medical - Diagnostics & Research

A PRODUCT MYRIAD GENETICS, INC. IS KNOWN FOR

Precise MRD (Minimal Residual Disease) Test
Precise MRD (Minimal Residual Disease) Test

The Precise MRD test is a tumor-informed, whole-genome sequencing assay for detecting circulating tumor DNA to monitor cancer recurrence and treatment response, with a commercial launch planned for March 2026.

COMPETITORS

COMPETITOR
ADPT COMPARE
GH COMPARE
NEO COMPARE
NTRA COMPARE

Revenue by Products

IconPRODUCTQ3-2020Q1-2021Q2-2021Q3-2021
Molecular Diagnostic Testing— $159.6M $178.7M ▲$167.3M ▼
Diagnostics$130.5M — — —
Other Segments$14.7M — — —
Molecular Diagnostic Prenatal Testing— $13.5M $10.7M ▼—

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$191.7M $196.5M ▲$187M ▼$214.3M ▲
NonUS$14M $13.3M ▼$13.4M ▲$13.2M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
114
LISTED HERE
25
RANKED BY POSITION SIZE
XBI
0.09% · 3.2M
VTS.AX
0.00% · 2.9M
XSU.TO
0.01% · 2.4M
FESM
0.04% · 771.5K
AVUV
0.01% · 660.0K
FNDA
0.02% · 446.1K
DFMC
0.01% · 225.4K
FSCC
0.16% · 179.6K
PRFZ
0.02% · 174.1K
SMIZ
0.20% · 170.4K
GSSC
0.05% · 157.7K
ISMD
0.11% · 121.4K
LABU
0.06% · 116.9K
XRSG.L
0.01% · 84.6K
HAPS
0.15% · 81.1K
GNOM
0.21% · 62.4K
VALT
0.29% · 28.9K
EES
0.01% · 19.7K
JPSE
0.01% · 16.7K
SQLV
0.12% · 16.0K
RTWP.L
0.02% · 12.1K
URTY
0.00% · 3.8K
DM
DMRS
0.15% · 2.3K
VETS
0.03% · 1.8K
RESM
0.01% · 174

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
389
TOP 12 OF 389 · RANKED BY POSITION SIZE
Orbimed Advisors LLC
125.0M sh · $122.88M
Blackrock, Inc.
15.3M sh · $94.12M
Blackrock Inc.
15.2M sh · $370.59M
Vanguard Group Inc
8.2M sh · $50.59M
Millennium Management LLC
6.7M sh · $41.21M
State Street Corp
6.0M sh · $36.69M
Vestal Point Capital, LP
5.7M sh · $32.75M
Glenview Capital Management, LLC
5.4M sh · $24.35M
D. E. Shaw & Co., Inc.
4.6M sh · $26.16M
Morgan Stanley
3.6M sh · $26.15M
Blackrock Fund Advisors
3.3M sh · $54.41M
Acadian Asset Management LLC
3.1M sh · $17.84M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book3
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Wheeler Benjamin Richard
Sale · 8.8K shares
2026-08-16
★
DIRECTOR:
Skovronsky Daniel
— · —
2026-06-23
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Raha Samraat S.
Purchase · 3.5K shares
2026-06-11
★
OFFICER: CHIEF COMMERICAL OFFICER
Donnelly Brian J
Purchase · 5.0K shares
2026-06-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
EQUAL WEIGHT 2
HOLD 1
NEUTRAL 1
OVERWEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
Stephens & Co. EQUAL WEIGHT Wells Fargo EQUAL WEIGHT TD Cowen HOLD UBS NEUTRAL Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
CDNA$49.79COMPARE
VIR$10.83COMPARE
PSNL$17.07COMPARE
AMN$34.62COMPARE
MRVI$7.68COMPARE
CSTL$33.50COMPARE
FLGT$19.61COMPARE
EVH$4.60COMPARE